CN Patent

CN103833630B — 氘化cftr增效剂

Assigned to Vertex Pharmaceuticals Europe Ltd · Expires 2018-11-13 · 8y expired

What this patent protects

本发明涉及式I的化合物及其药学上可接受的盐。本发明还提供了包含本发明化合物的组合物，以及这样的组合物在通过施用CFTR增效剂有益治疗的疾病和病症的治疗方法中的用途。

USPTO Abstract

本发明涉及式I的化合物及其药学上可接受的盐。本发明还提供了包含本发明化合物的组合物，以及这样的组合物在通过施用CFTR增效剂有益治疗的疾病和病症的治疗方法中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN103833630B
Jurisdiction
CN
Classification
—
Expires
2018-11-13
Drug substance claim
No
Drug product claim
No
Assignee
Vertex Pharmaceuticals Europe Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.